ClearPoint Neuro (CLPT) delivered its strongest growth quarter of the year, but the details give bears as much to work with as bulls. The company lost $0.24 per share, 25.0% better than the -$0.32 consensus. Revenue rose 36.3% to $12.08 million, an acceleration from 18% growth in the second quarter, yet it still missed the $12.5 million consensus by 3.4%. The loss also widened from $0.21 a year ago, which translates to a 14.3% year-over-year earnings decline. That is the central tension: the top line is clearly accelerating and spending has been brought back under control, but the full-year outlook keeps drifting lower and the balance sheet is now being supported by equity issuance.
The quality of the beat deserves scrutiny. Much of the growth is inorganic. Neurosurgery navigation and therapy revenue jumped 59% to $5.4 million, driven primarily by IRRAflow, which came with the IRRAS acquisition in late 2025. Management did say organic clinical disposables also grew. The more encouraging organic signal came from biologics and drug delivery, which returned to 11% growth at $4.9 million after falling 15% in the second quarter, helped by services at ClearPoint Advanced Laboratories (CAL). Capital equipment and software set a record at $1.7 million, up 68%. Gross margin, however, slid to 58% from 63% a year earlier, and it has now fallen every quarter this year: 64% in Q1, 62% in Q2, and 58% in Q3. Management attributed the decline to CAL facility overhead and amortization of acquired intangibles. Below the operating line, interest expense rose to $1.4 million from $0.9 million, which helps explain why a 36% revenue gain still produced a larger net loss of $7.5 million.
The call's most constructive message was operating leverage. Operating expenses rose 23% year over year to $13.4 million, but they fell sharply from nearly $17 million in Q2. That drop included a more than 15% sequential cut in sales and marketing after a commercial reorganization. Implied cash burn eased to roughly $5 million from about $7 million in Q2, and the CFO is targeting gradual burn reduction over the next four to six quarters. Management's tone was noticeably more confident than in Q2, which had been framed around a guidance cut and a revenue shortfall against internal plans. Executives described the capital equipment funnel as the largest in company history, tied to new sites joining partner Phase 3 trials.
The forward picture is where expectations reset again. Full-year 2026 revenue guidance is now $48 million to $50 million. Earnings Whispers characterizes that as in line, but the midpoint has slipped from $50 million in Q2 and from an original $52 million to $56 million range. Nine-month revenue of $35.1 million implies a sizable fourth-quarter step-up, and management acknowledged that it depends on lumpy capital deal timing. The 2027 framing also softened to "mid-teens" base growth, down from "high teens, if not 20%" last quarter, and formal guidance was deferred.
The catalyst list is real but back-end loaded. uniQure has submitted its AMT-130 BLA for Huntington's disease, with ClearPoint's device documentation on file and a companion 510(k) planned once the FDA accepts the filing. Management sees potential approval in mid-to-second-half 2027 if everything proceeds on schedule, but acceptance is still pending. The NCI-funded spine laser program is early-stage research with an undefined regulatory path. Full-scope CAL and GLP study revenue is largely a 2027 story, and the IRRAflow CSF-management franchise has five milestones targeted for next year.
The financing picture tempers the optimism. ClearPoint raised $22.0 million in net proceeds through its first use of the at-the-market program. That lifted cash to $46.2 million, but operations consumed $20.1 million year-to-date, and the company carries $50.8 million in notes. The share count rose to 32.1 million from 29.4 million at year-end, and further CAL capital spending is coming.
The market had already priced in deep skepticism before the report. Shares fell 35% from the $14.91 open after the August report to $9.69, sitting 25.7% below the 200-day moving average. The stock touched an inter-earnings low of $8.91 just two days before results, well off the August 25 high of $17.22. Investor sentiment deteriorated meaningfully, from -0.44 to -0.71. Price and AVWAP trend readings remain negative, although sequential growth registers as positive, consistent with the reacceleration in revenue.
The bottom line is that ClearPoint showed it can grow faster while spending less, which turnaround skeptics may not have been positioned for. However, a third consecutive reduction in the guidance midpoint, falling gross margins, softer 2027 framing and dilutive financing leave the burden of proof on execution. The fourth-quarter capital ramp and FDA acceptance of the AMT-130 BLA are the next tests of whether this rebound is durable.